4.4 Article

Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion - Nadir+2?

Journal

UROLOGY
Volume 72, Issue 2, Pages 389-393

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.urology.2007.10.053

Keywords

-

Ask authors/readers for more resources

OBJECTIVES The new American Society for Therapeutic Radiology and Oncology/Radiation Therapy Oncology Group consensus definition of biochemical failure after radiotherapy for prostate cancer is defined as a prostate-specific antigen level at or greater than the absolute nadir PSA level plus 2 ng/mL. Bccause this definition inevitably will be used to compare cancer control rates after radiotherapy to those after Surgery, this study examined the effect of this comparison. METHODS We reviewed the data from 2570 men who had undergone radical prostatectomy from 1985 to 2004. Biochemical failure was defined as any measurable PSA level Of 0.2 ng/mL or greater. We evaluated how the nadir+2 definition affected the failure rate when applied to this series. RESULTS The actuarial 5, 10, and 15-year biochemical recurrence-free survival probability with failure defined as a PSA level of 0.2 ng/mL or more and a PSA level of 2 ng/mL or more was 88.6% 81.2%, and 78.1% and 94.6%, 89.4%, and 84.3%), respectively (P < 0.0001). The median time to biochemical progression was 2.8 years for the greater than 0.2 ng/mL definition and 7.9 years for the 2 ng/mL or more definition. The nadir+2 definition systematically overestimated the biochemical recurrence-free survival, even after stratifying patients into standard prognostic risk groups, especially in men who developed local recurrence. CONCLUSIONS When applied to a mature series of surgically treated patients with localized prostate cancer, the American Society for Therapeutic Radiology and Oncology nadir+2 definition resulted in a systematic delay in the determination of biochemical failure. Because patients in this series who experienced a detectable PSA level took more than 5 years to progress to a PSA level of 2 ng/mL or greater, the 5-year biochemical control rates with the definition of 0.2 ng/mL or more should be compared with the 10-year biochemical control rates using the nadir+2 definition.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Urology & Nephrology

Characterising potential bone scan overuse amongst men treated with radical prostatectomy

Peter S. Kirk, Tudor Borza, Megan E. V. Caram, Dean A. Shumway, Danil V. Makarov, Jennifer A. Burns, Jeremy B. Shelton, John T. Leppert, Christina Chapman, Michael Chang, Brent K. Hollenbeck, Ted A. Skolarus

BJU INTERNATIONAL (2019)

Article Urology & Nephrology

Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: US Food and Drug Administration Oncology Center of Excellence Public Workshop

Chana Weinstock, Daniel Suzman, Paul Kluetz, John Baxley, Charles Viviano, Amna Ibrahim, Jonathan Jarow, Raejshwari Sridhara, Ke Liu, Peter Carroll, Scott Eggener, Jim C. Hu, Maha Hussain, Martin King, Eric Klein, Terry Kungel, Danil Makarov, Peter A. Pinto, Brian Rini, Mack Roach, Howard Sandler, Peter N. Schlegel, Daniel Song, Kirsten Goldberg, Richard Pazdur, Julia A. Beaver

JOURNAL OF UROLOGY (2020)

Article Oncology

Life expectancy estimates for patients diagnosed with prostate cancer in the Veterans Health Administration

Ericka M. Sohlberg, I-Chun Thomas, Jaden Yang, Kristopher Kapphahn, Timothy J. Daskivich, Ted A. Skolarus, Jeremy B. Shelton, Danil V. Makarov, Jonathan Bergman, Christine Ko Bang, Mary K. Goldstein, Todd H. Wagner, James D. Brooks, Manisha Desai, John T. Leppert

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2020)

Article Urology & Nephrology

A Clinical Reminder Order Check Intervention to Improve Guideline- concordant Imaging Practices for Men With Prostate Cancer: A Pilot Study

Shannon E. Ciprut, Matthew D. Kelly, Dawn Walter, Renee Hoffman, Daniel J. Becker, Stacy Loeb, Erica Sedlander, Craig T. Tenner, Scott E. Sherman, Steven B. Zeliadt, Danil Makarov

UROLOGY (2020)

Article Oncology

The Association of Veterans' PSA Screening Rates With Changes in USPSTF Recommendations

Daniel J. Becker, Temitope Rude, Dawn Walter, Chan Wang, Stacy Loeb, Huilin Li, Shannon Ciprut, Matthew Kelly, Steven B. Zeliadt, Angela Fagerlin, Herbert Lepor, Scott Sherman, Joseph E. Ravenell, Danil Makarov

Summary: Analyzing the trends of PSA screening among veterans before and after the 2012 USPSTF recommendation, overall PSA screening rates in the VA only decreased modestly, continuing for more than one-half of the men in the study. Veterans of different races had similar screening rates, pointing to VA care potentially reducing racial disparities. Veterans of varying ages experienced statistically significant differences in PSA screening trends.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

Editorial Material Andrology

Urologist-led smoking cessation: a way forward through implementation science

Richard S. Matulewicz, Danil V. Makarov, Scott E. Sherman, Sarah A. Birken, Marc A. Bjurlin

TRANSLATIONAL ANDROLOGY AND UROLOGY (2021)

Article Urology & Nephrology

Tobacco Screening and Treatment during Outpatient Urology Office Visits in the United States

Ari P. Bernstein, Marc A. Bjurlin, Scott E. Sherman, Danil Makarov, Erin Rogers, Richard S. Matulewicz

Summary: The study evaluated how often urologists screen for and provide treatment for tobacco-related conditions in outpatient settings. It found that approximately a third of urology visits were related to smoking, with 70% including tobacco screening but only 7% involving counseling for current smokers.

JOURNAL OF UROLOGY (2021)

Article Medicine, Research & Experimental

Randomized trial of community health worker-led decision coaching to promote shared decision-making for prostate cancer screening among Black male patients and their providers

Danil V. Makarov, Zachary Feuer, Shannon Ciprut, Natalia Martinez Lopez, Angela Fagerlin, Michele Shedlin, Heather T. Gold, Huilin Li, Gina Lynch, Rueben Warren, Peter Ubel, Joseph E. Ravenell

Summary: This study aims to evaluate the efficacy of a community health worker (CHW)-led decision-coaching program to facilitate shared decision-making for prostate cancer screening among Black men in primary care settings, with the ultimate goal of improving decision quality. The study will enroll Black male patients and providers at a clinical site to assess the impact of decision coaching on PSA screening decisions, with primary outcome measures including knowledge, PSA screening rates, acceptability, and feasibility of the intervention. The intervention is hypothesized to result in preference-congruent decisions and improved physician satisfaction with counseling patients about prostate cancer screening.

TRIALS (2021)

Article Urology & Nephrology

Population-Level Assessment of Smoking-Related Beliefs and Behaviors Among Survivors of Genitourinary Cancers: An Application of the Theory of Planned Behavior

Lee Brake, Akya Myrie, Calvin Zhao, Zach Feuer, Jacob Taylor, Marc A. Bjurlin, Scott E. Sherman, Danil Makarov, Richard S. Matulewicz

Summary: This study aimed to describe attitudes, perceptions, and beliefs related to smoking and smoking cessation among survivors of genitourinary cancers using a theory-based framework. The results showed significant variation in behaviors and perceptions related to smoking and smoking cessation among the study population. Most participants perceived smoking as harmful to health, with a majority being regretful about starting smoking, yet only a small percentage had used prescription medication or nicotine replacement therapy for smoking cessation. Personalized smoking cessation interventions may be necessary for optimal success.

UROLOGY (2021)

Article Oncology

COVID-19 outcomes in hospitalized patients with active cancer: Experiences from a major New York City health care system

Chen Fu, James H. Stoeckle, Lena Masri, Abhishek Pandey, Meng Cao, Dalia Littman, Marissa Rybstein, Sunil E. Saith, Kinan Yarta, Abhinav Rohatgi, Danil V. Makarov, Scott E. Sherman, Christy Morrissey, Alexander C. Jordan, Beatrice Razzo, Poy Theprungsirikul, Joseph Tsai, Daniel J. Becker

Summary: The study found that hospitalized patients with active cancer were more likely to die from COVID-19, with those with hematologic cancers at the highest risk of death. Patients who received cancer therapy within 3 months before hospitalization did not have an increased risk of death.

CANCER (2021)

Article Oncology

Interaction between race and prostate cancer treatment benefit in the Veterans Health Administration

Temitope Rude, Dawn Walter, Shannon Ciprut, Matthew D. Kelly, Chan Wang, Angela Fagerlin, Aisha T. Langford, Herbert Lepor, Daniel J. Becker, Huilin Li, Stacy Loeb, Joseph Ravenell, John T. Leppert, Danil V. Makarov

Summary: Studies show that Black men may undergo definitive prostate cancer treatment less often than men of other races. However, the relationship varies in the context of the patient's treatment benefit, with Black men receiving less definitive treatment in high-benefit situations. Further investigation is needed into the driving forces behind this persistent disparity.

CANCER (2021)

Article Oncology

The cost, survival, and quality-of-life implications of guideline-discordant imaging for prostate cancer

Aaron N. Winn, Matthew Kelly, Shannon Ciprut, Dawn Walter, Heather T. Gold, Steven B. Zeliadt, Scott E. Sherman, Danil V. Makarov

Summary: This study used a microsimulation model to investigate the impact of imaging based on guidelines on healthcare costs and patient health outcomes. The results showed that ideal upfront imaging according to guidelines can reduce medical costs and slightly improve health outcomes compared to current practices.

CANCER REPORTS (2022)

Article Substance Abuse

A Population-Level Assessment of Smoking Cessation following a Diagnosis of Tobacco- or Nontobacco-Related Cancer among United States Adults

Richard S. Matulewicz, Marc A. Bjurlin, Zachary Feuer, Danil Makarov, Scott E. Sherman, Joy Scheidell, Maria R. Khan, Omar El-Shahawy

Summary: This study examined the association between cancer diagnosis and subsequent smoking cessation, finding that individuals diagnosed with tobacco-related cancer were more likely to quit smoking compared to those with non-tobacco-related cancer. This suggests that a cancer diagnosis, especially related to tobacco, can lead to significant behavioral changes such as smoking cessation.

JOURNAL OF SMOKING CESSATION (2021)

Article Oncology

Patient Perspectives on the Implementation of Risk-Aligned Bladder Cancer Surveillance: Systematic Evaluation Using the Tailored Implementation for Chronic Diseases Framework

Florian R. Schroeck, Amanda St Ivany, William Lowrance, Danil V. Makarov, Philip P. Goodney, Lisa Zubkoff

JCO ONCOLOGY PRACTICE (2020)

Review Urology & Nephrology

Exploring Variation in the Use of Conservative Management for Low -risk Prostate Cancer in the Veterans Affairs Healthcare System

Stacy Loeb, Nataliya K. Byrne, Binhuan Wang, Danil V. Makarov, Daniel Becker, David R. Wise, Herbert Lepor, Dawn Walter

EUROPEAN UROLOGY (2020)

No Data Available